DMK Pharmaceuticals Corporation
DMKPQ · OTC
9/30/2023 | 6/30/2023 | 3/31/2023 | 12/31/2022 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | -$0 | $0 | -$0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 30.5% | -99.5% | -32.4% | – |
| Gross Profit | -$0 | -$0 | -$0 | -$0 |
| % Margin | -3,658.8% | -6,263.4% | -30.1% | -32.5% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -18,811% | -99,014.1% | -434.8% | -141.1% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -15,317.2% | -123,457.5% | -615.5% | -154.7% |
| EPS Diluted | -0.2 | -3.34 | -4.09 | -1.55 |
| % Growth | 94% | 18.3% | -163.9% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | $0 | $0 | $0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |